Stockholm, November 7, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference in New York, NY. Read more…
Webcast to be held on: May 26, 2023 at 08:00 EST/14:00 CET Stockholm, May 17, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, will hold a webcast including a Q&A session to present interim results from the phase 2a trial […]
alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA[1] filing planned for H2 2023 DSR® (Direct Sodium Removal) – clinical evidence of disease-modifying heart failure drug therapy, on track to start US Phase 1/2a MOJAVE study in Q2 2023 Total cash position of €18.9 million at end 2022 and cash runway […]
Emcitate® (tiratricol) is the first potential treatment of MCT8 deficiency, a rare genetic disease with high unmet medical need and no available treatment. Egetis will host a webcast today at 15:00 CET (9:00am ET) Stockholm, Sweden, January 18, 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) (the “Company”) today announced that in recent regulatory interactions, […]
